Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes

Geriatrics and Gerontology International

Volumn 8, Issue 4, 2008, Pages 218-226

  Okamoto, Takashi ^a   Okamoto, Lisa ^a   Lisanti, Michael P ^b   Akishita, Masahiro ^c  

^a Okhotsk kai Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Insulin injection; Oral hypoglycemic agent; Switch therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; INOSITOL; INSULIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; VOGLIBOSE;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 56649103478     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2008.00477.x     Document Type: Article

References (33)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
2. Warren R, Frier B. Hypoglycaemia and cognitive function. Diabetes Obes Metab 2005; 7: 493-503.
3. Kanda Y, Yamada K, Harada Y et al. Clinical parameters for predicting possibility of insulin therapy withdrawal in patients with type 2 diabetes mellitus. J Jpn Diabetes Soc 2004; 47: 271-275.
4. Shichiri M, Ohkubo Y, Kishikawa H et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl. 2): B21-B29.
5. Yki-Jarvinen H. Drug therapy: Thiazolidinediones. N Engl J Med 2004; 35: 1106-1118.
6. Kubota N, Terauchi Y, Kubota T et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006; 281: 8748-8755.
7. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Int Med 1999; 131: 281-303.
8. Dormandy J, Charbonnel B, Eckland D etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitaAzone Clinical Trial in macroVascular events): A randomized controlled trial. Lancet 2005; 366: 1279-1289.
9. Koshiba K, Nomura M, Nakaya Y et al. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006; 53: 87-94.
10. Marti S, Kolb H, Beuth J etal. Changes in patients' body weight after 12months of treatment with glimepiride or glibenclamide in type 2 diabetes: A multicentre retrospective cohort study. Diabetologia 2003; 46: 1611-1617.
11. Inoue K, Ikegami H, Fujisawa T et al. Less frequent body weight gain in elderly type 2 diabetic patients treated with glimepiride. Geriatr Gerontol Int 2003; 3: 56-59.
12. Saito N, Sakai H, Suzuki S et al. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. J Int Med Res 1998; 26: 219-232.
13. Ishida H, Kato S, Nishimura M et al. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. Horm Metab Res 1998; 30: 673-678.
14. The Expert Committee on the Diagnosis and Classification of Diabetes Melittus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
15. Kobayashi M, Yamazaki K, Hirano K et al. The status of diabetes control and antidiabetic drug therapy in Japan-A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diabetes Res Clin Pract 2006; 73: 198-204.
16. Schmitz O, Charbonnel B, Scheen A. Pioglitazone reduces insulin requirements and improves glycemic control in insulin-treated patients with type 2 diabetes: Results from PROactive. Presented as a poster in the European Diabetes Association Conference in 2006.
17. Stern P, Haffner S. Dyslipidemia in type II diabetes. Diabets Care 1991; 14: 1144-1159.
18. Agardh C, Nilsson-Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982; 5: 322-325.
19. Cheng A, Zinman B. Principles of insulin therapy. In: Kahn CR, Weir GC, King GL et al., eds. Joslin's Diabetes Mellitus, 14th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 659-669.
20. Waugh J, Keating G, Plosker G etal. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs 2006; 66: 85-109.
21. Langenfeld M, Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation 2005; 111: 2525-2531.
22. Watanabe I, Tani S, Anazawa T et al. Pioglitazone on artheriosclerosis in comparison with that of glibencamide. Diabetes Res Clin Pract 2005; 68: 104-110.
23. McGuire D, Newby L, Bhapkar M et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004; 147: 246-252.
24. Despres J, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
25. Wilcox R, Bousser M, Betteridge D et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873.
26. Arai Y, Nakazawa S, Kojima T et al. High adiponectin concentration and its role for longevity in female centenarians. Geriatr Gerontol Int 2006; 6: 32-39.
27. Kalmijn S, Feskens E, Launer L et al. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995; 38: 1096-1102.
28. Luchsinger J, Tang M, Shea S et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-1192.
29. Kuusisto J, Koivisto K, Mykkanen L et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. BMJ 1997; 315: 1045-1049.
30. Biessels G, Staekenborg S, Brunner E et al. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 2006; 5: 64-74.
31. Ott A, Stolk R, van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942.
32. Curb J, Rodriguez B, Abbott R et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999; 52: 971-975.
33. Luchsinger J, Tang M, Stern Y et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635-641.